B-type natriuretic peptide in cardiovascular disease

Research output: Contribution to journalArticle

786 Citations (Scopus)

Abstract

Natriuretic peptide hormones, a family of vasoactive peptides with many favourable physiological properties, have emerged as important candidates for development of diagnostic tools and therapeutic agents in cardiovascular disease. The rapid incorporation into clinical practice of bioassays to measure natriuretic peptide concentrations, and drugs that augment the biological actions of this system, show the potential for translational research to improve patient care. Here, we focus on the physiology of the natriuretic peptide system, measurement of circulating concentrations of B-type natriuretic peptide (BNP) and the N-terminal fragment of its prohormone (N-terminal BNP) to diagnose heart failure and left ventricular dysfunction, measurement of BNP and N-terminal BNP to assess prognosis in patients with cardiac abnormalities, and use of recombinant human BNP (nesiritide) and vasopeptidase inhibitors to treat heart failure.

Original languageEnglish (US)
Pages (from-to)316-322
Number of pages7
JournalLancet
Volume362
Issue number9380
DOIs
StatePublished - Jul 26 2003

Fingerprint

Brain Natriuretic Peptide
Cardiovascular Diseases
Natriuretic Peptides
Heart Failure
Translational Medical Research
Left Ventricular Dysfunction
Biological Assay
Patient Care
Peptides
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

B-type natriuretic peptide in cardiovascular disease. / de Lemos, James A; McGuire, Darren K; Drazner, Mark H.

In: Lancet, Vol. 362, No. 9380, 26.07.2003, p. 316-322.

Research output: Contribution to journalArticle

@article{391b2246fa3f411bb306064a8ed087ef,
title = "B-type natriuretic peptide in cardiovascular disease",
abstract = "Natriuretic peptide hormones, a family of vasoactive peptides with many favourable physiological properties, have emerged as important candidates for development of diagnostic tools and therapeutic agents in cardiovascular disease. The rapid incorporation into clinical practice of bioassays to measure natriuretic peptide concentrations, and drugs that augment the biological actions of this system, show the potential for translational research to improve patient care. Here, we focus on the physiology of the natriuretic peptide system, measurement of circulating concentrations of B-type natriuretic peptide (BNP) and the N-terminal fragment of its prohormone (N-terminal BNP) to diagnose heart failure and left ventricular dysfunction, measurement of BNP and N-terminal BNP to assess prognosis in patients with cardiac abnormalities, and use of recombinant human BNP (nesiritide) and vasopeptidase inhibitors to treat heart failure.",
author = "{de Lemos}, {James A} and McGuire, {Darren K} and Drazner, {Mark H}",
year = "2003",
month = "7",
day = "26",
doi = "10.1016/S0140-6736(03)13976-1",
language = "English (US)",
volume = "362",
pages = "316--322",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9380",

}

TY - JOUR

T1 - B-type natriuretic peptide in cardiovascular disease

AU - de Lemos, James A

AU - McGuire, Darren K

AU - Drazner, Mark H

PY - 2003/7/26

Y1 - 2003/7/26

N2 - Natriuretic peptide hormones, a family of vasoactive peptides with many favourable physiological properties, have emerged as important candidates for development of diagnostic tools and therapeutic agents in cardiovascular disease. The rapid incorporation into clinical practice of bioassays to measure natriuretic peptide concentrations, and drugs that augment the biological actions of this system, show the potential for translational research to improve patient care. Here, we focus on the physiology of the natriuretic peptide system, measurement of circulating concentrations of B-type natriuretic peptide (BNP) and the N-terminal fragment of its prohormone (N-terminal BNP) to diagnose heart failure and left ventricular dysfunction, measurement of BNP and N-terminal BNP to assess prognosis in patients with cardiac abnormalities, and use of recombinant human BNP (nesiritide) and vasopeptidase inhibitors to treat heart failure.

AB - Natriuretic peptide hormones, a family of vasoactive peptides with many favourable physiological properties, have emerged as important candidates for development of diagnostic tools and therapeutic agents in cardiovascular disease. The rapid incorporation into clinical practice of bioassays to measure natriuretic peptide concentrations, and drugs that augment the biological actions of this system, show the potential for translational research to improve patient care. Here, we focus on the physiology of the natriuretic peptide system, measurement of circulating concentrations of B-type natriuretic peptide (BNP) and the N-terminal fragment of its prohormone (N-terminal BNP) to diagnose heart failure and left ventricular dysfunction, measurement of BNP and N-terminal BNP to assess prognosis in patients with cardiac abnormalities, and use of recombinant human BNP (nesiritide) and vasopeptidase inhibitors to treat heart failure.

UR - http://www.scopus.com/inward/record.url?scp=0042198675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042198675&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(03)13976-1

DO - 10.1016/S0140-6736(03)13976-1

M3 - Article

VL - 362

SP - 316

EP - 322

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9380

ER -